ATE391136T1 - Fas peptide und antikörper zur modulierung von apoptosis - Google Patents

Fas peptide und antikörper zur modulierung von apoptosis

Info

Publication number
ATE391136T1
ATE391136T1 AT99931070T AT99931070T ATE391136T1 AT E391136 T1 ATE391136 T1 AT E391136T1 AT 99931070 T AT99931070 T AT 99931070T AT 99931070 T AT99931070 T AT 99931070T AT E391136 T1 ATE391136 T1 AT E391136T1
Authority
AT
Austria
Prior art keywords
antibodies
fas
peptides
modulating apoptosis
cellular proliferation
Prior art date
Application number
AT99931070T
Other languages
English (en)
Inventor
Francesca Chiodi
Original Assignee
Imed Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813194.9A external-priority patent/GB9813194D0/en
Priority claimed from GBGB9905793.7A external-priority patent/GB9905793D0/en
Application filed by Imed Ab filed Critical Imed Ab
Application granted granted Critical
Publication of ATE391136T1 publication Critical patent/ATE391136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99931070T 1998-06-18 1999-06-15 Fas peptide und antikörper zur modulierung von apoptosis ATE391136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9813194.9A GB9813194D0 (en) 1998-06-18 1998-06-18 Methods and means for modulating apoptosis
GBGB9905793.7A GB9905793D0 (en) 1998-06-18 1999-03-12 Methods and means for modulating apoptosis

Publications (1)

Publication Number Publication Date
ATE391136T1 true ATE391136T1 (de) 2008-04-15

Family

ID=26313898

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931070T ATE391136T1 (de) 1998-06-18 1999-06-15 Fas peptide und antikörper zur modulierung von apoptosis

Country Status (9)

Country Link
US (1) US6846637B1 (de)
EP (1) EP1087993B1 (de)
AT (1) ATE391136T1 (de)
AU (1) AU4772299A (de)
DE (1) DE69938451T2 (de)
DK (1) DK1087993T3 (de)
ES (1) ES2306515T3 (de)
PT (1) PT1087993E (de)
WO (1) WO1999065935A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099845A2 (en) 2002-05-23 2003-12-04 Trustees Of The University Of Pennsylvania Fas peptide mimetics and uses thereof
EP2322559A3 (de) 2002-07-04 2011-08-03 Patrys Limited Neoplasma-spezifische Antikörper und deren Verwendungen
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
US7592143B2 (en) * 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
EP2343321A1 (de) * 2003-11-12 2011-07-13 Patrys Limited Humane karzinomspezifische Antikörper
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
US9309320B2 (en) 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
AU2010223569A1 (en) * 2009-03-12 2011-11-03 Imed Ab Human antibodies against human Fas and their use
JP6297552B2 (ja) 2012-07-18 2018-03-20 アポジェニックス アーゲー Mdsの治療のための、cd95シグナル伝達経路阻害剤
CA2922704A1 (en) 2013-05-24 2014-11-27 Neil R. Cashman Cell senescence markers as diagnostic and therapeutic targets
EP2898896A1 (de) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Mittel zur Verwendung bei der Behandlung von Netzhautentzündung
EP3131922B1 (de) * 2014-04-17 2020-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptide und verwendungen davon zur verringerung von cd95-vermittelter zellmotilität
EP3076179A1 (de) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnose und behandlung von minderwertigen glioma
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
CN114269370A (zh) 2019-03-29 2022-04-01 迈斯特治疗公司 离体产生t细胞治疗剂的方法以及相关的组合物和方法
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4110799B1 (de) 2020-02-27 2024-11-06 Turnstone Biologics Corp. Verfahren zur ex-vivo-anreicherung und vermehrung von tumorreaktiven t-zellen und verwandten zusammensetzungen davon
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69009497T2 (de) 1990-01-19 1994-11-24 German Cancer Research Center, 6900 Heidelberg Mit zellularer apoptosis assoziiertes zelloberflächenantigen.
CA2067031C (en) 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
US5830469A (en) 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
NZ275711A (en) 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US5663070A (en) * 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
JPH08157500A (ja) * 1994-12-08 1996-06-18 Oriental Yeast Co Ltd Fas抗原の定量法
WO1997012632A1 (en) 1995-10-05 1997-04-10 Tkb Associates Limited Partnership Methods for treatment of diseases associated with a deficiency of fas ligand activity
DE19544332C2 (de) * 1995-11-28 1999-07-08 Deutsches Krebsforsch Verfahren zum Nachweis der Expression von CD95 Ligand in Zellen
JP3663243B2 (ja) * 1995-12-14 2005-06-22 株式会社医学生物学研究所 Fas抗原の免疫学的測定法及び測定用キット
AU724579B2 (en) 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor
US5912168A (en) * 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
AU736287B2 (en) 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
KR20020008197A (ko) 1999-05-24 2002-01-29 가와무라 요시부미 항-Fas 항체를 함유하는 의약 조성물

Also Published As

Publication number Publication date
DE69938451D1 (de) 2008-05-15
DE69938451T2 (de) 2009-04-09
WO1999065935A2 (en) 1999-12-23
DK1087993T3 (da) 2008-07-14
EP1087993B1 (de) 2008-04-02
US6846637B1 (en) 2005-01-25
AU4772299A (en) 2000-01-05
PT1087993E (pt) 2008-07-04
EP1087993A1 (de) 2001-04-04
WO1999065935A3 (en) 2003-04-17
ES2306515T3 (es) 2008-11-01

Similar Documents

Publication Publication Date Title
DE69938451D1 (de) Fas peptide und antikörper zur modulierung von apoptosis
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
EP1019365A4 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
NO20000934D0 (no) Adipocyttspesifikke proteinhomologer
DE60041452D1 (de) CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN
MXPA04002808A (es) Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos.
DE69833014D1 (de) Menschliche toll homologen
CA2321177A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
PL338139A1 (en) Protein homologues specific for adipocytes
EP1517144A3 (de) Verfahren zur Identifizierung eines Antikörpers, der einen humanen Vanilloid Rezeptor bindet und dessen Aktivität moduliert
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
NZ514091A (en) Vascular adhesion molecules and modulation of their function
MXPA02011002A (es) Oligopeptidos para promover el crecimiento del cabello.
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
WO2004109290A3 (en) Methods for identifying modulators of kinesin activity
WO2002090544A3 (en) Protein-protein interactions in adipocyte cells (3)
DE69939593D1 (de) Polypeptide zur modulierung des überlebens von zellen
BR0207253A (pt) Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado
DE60333669D1 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
CY1109378T1 (el) Fas πεπτιδια και αντισωματα για ρυθμιση αποπτωσης
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
EP2236619A3 (de) BCL2L12-Polypeptidaktivatoren und -inhibitoren
DE69806107D1 (de) Methoden und reagenzien zur regulierung von apoptosis
WO2003075014A3 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1087993

Country of ref document: EP